Medical Journals

Repeated Delta1-opioid Receptor Stimulation Reduces Delta2-opioid Receptor Responses in the Sa Node.

Authors:
  • Deo S H
  • Johnson-Davis S
  • Barlow M A
  • Yoshishige D
  • Caffrey J L

From: Dept. of Integrative Physiology, Univ. of North Texas Health Science Center, 3500 Camp Bowie Blvd., Fort Worth TX 76107, USA. caffreyj@hsc.unt.edu

American journal of physiology. Heart and circulatory physiology

  • Publish Date: Nov 2006
  • ISSN: 0363-6135
  • Volume: 291
  • Issue: 5
  • Pages: H2246-54
  • Medium: Print
  • Language: English
  • Citation (JAMA): Deo S H, Johnson-Davis S, Barlow M A, et al. Repeated Delta1-opioid Receptor Stimulation Reduces Delta2-opioid Receptor Responses in the Sa Node.. Am. J. Physiol. Heart Circ. Physiol. Nov 2006;291:H2246-54

Abstract

Ultra-low-dose methionine-enkephalin-arginine-phenylalanine improves vagal transmission (vagotonic) and decreases heart rate via delta(1)-opioid receptors within the sinoatrial (SA) node. Higher doses activate delta(2)-opioid receptors, interrupt vagal transmission (vagolytic), and reduce the bradycardia. Preconditioning-like occlusion of the nodal artery produced a vagotonic response that was reversed by the delta(1)-antagonist 7-benzylidenaltrexone (BNTX). The following study tested the hypothesis that extended delta(1)-opioid receptor stimulation reduces subsequent delta(2)-receptor responses. The delta(2)-agonist deltorphin II was introduced in the SA node by microdialysis to evaluate delta(2) responses before and after infusion of the delta(1)-agonist TAN-67. TAN-67 reduced the vagolytic effect of deltorphin by two-thirds. When the delta(1)-antagonist BNTX was combined with TAN-67, the deltorphin response was preserved, suggesting that attrition of the prior response was mediated by delta(1) activity. When TAN-67 was omitted in time control studies, some loss of delta(2) responses was apparent in the absence of the delta(1) treatment. This loss was also eliminated by BNTX, suggesting that the attenuation of the response after deltorphin alone was also the result of delta(1) activity. Additional studies tested TAN-67 alone in the absence of prior deltorphin. When time controls were conducted without the initial deltorphin treatment, a robust vagolytic response was observed. When TAN-67 preceded the delayed deltorphin, the vagolytic response was eroded, indicating an independent effect of TAN-67. BNTX infused afterward was unable to restore the delta(2) response. These data support the conclusion that the loss of the delta(2) response resulted from reduced delta(2) activity mediated by continued delta(1)-receptor stimulation and not the arithmetic consequence of increased competition from that same delta(1) receptor.

Mesh Headings (Keywords): Analgesics, Analgesics, Opioid, Animals, Benzylidene Compounds, Bradycardia, Dogs, Dose-Response Relationship, Drug, Enkephalin, Methionine, Female, Male, Microdialysis, Naltrexone, Narcotic Antagonists, Oligopeptides, Quinolines, Receptors, Opioid, delta, Sinoatrial Node, Stimulation, Chemical, Vagus Nerve


Check for Full Text / PubMed Unique Identifier (PMID): 16782849


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.